References
- Lees AJ , HardyJ , ReveszT . Parkinson’s disease . Lancet373 , 2055 – 2066 ( 2009 ).
- Foltynie T , BrayneC , BarkerRA . The heterogeneity of idiopathic Parkinson’s disease . J. Neurol.249 , 138 – 145 ( 2002 ).
- Marras C , LangA . Parkinson’s disease subtypes: lost in translation?J. Neurol. Neurosurg. Psychiatry84 , 409 – 415 ( 2013 ).
- Thenganatt MA , JankovicJ . Parkinson disease subtypes . JAMA Neurol.7 , 499 – 504 ( 2014 ).
- Riedel O , BittersD , AmannU , GarbeE , LangnerI . Estimating the prevalence of Parkinson’s disease (PD) and proportions of patients with associated dementia and depression among the older adults based on secondary claims data . Int. J. Geriatr. Psychiatry31 , 938 – 943 ( 2016 ).
- Hirsch L , JetteN , FrolkisA , SteevesT , PringsheimT . The incidence of Parkinson’s disease: a systematic review and meta-analysis . Neuroepidemiology46 , 292 – 300 ( 2016 ).
- Pringsheim T , JetteN , FrolkisA , SteevesTD . The prevalence of Parkinson’s disease: a systematic reviewand meta-analysis . Mov. Disord.29 , 1583 – 1590 ( 2014 ).
- Cacabelos R . Parkinson’s disease: from pathogenesis to pharmacogenomics . Int. J. Mol. Sci.18 ( 3 ), pii:E551 ( 2017 ).
- Ahlskog JE , MuenterMD . Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature . Mov. Disord.16 ( 3 ), 448 – 458 ( 2001 ).
- Sharma JC , BachmannCG , LinazasoroG . Classifying risk factors for dyskinesia in Parkinson’s disease . Parkinsonism Relat. Disord.16 ( 8 ), 490 – 497 ( 2010 ).
- Rieck M , Schumacher-SchuhAF , AltmannVet al. DRD2 haplotype is associated with dyskinesia induced by levodopa therapy in Parkinson’s disease patients . Pharmacogenomics13 , 1701 – 1710 ( 2012 ).
- Factor SA . Current status of symptomatic medical therapy in Parkinson’s disease . Neurotherapeutics5 , 164 – 180 ( 2008 ).
- Kalinderi K , FidaniL , KatsarouZ , BostantjopoulouS . Pharmacological treatment and the prospect of pharmacogenetics in Parkinson’s disease . 65 , 1289 – 1294 ( 2011 ).
- Schumacher-Schuh AF , RiederCR , HutzMH . Parkinson’s disease pharmacogenomics: new findings and perspectives . Pharmacogenomics15 , 1253 – 1271 ( 2014 ).
- Payami H , FactorSA . Promise of pharmacogenomics for drug discovery, treatment and prevention of Parkinson’s disease. A perspective . Neurotherapeutics11 , 111 – 116 ( 2014 ).
- Payami H . The emerging science of precision medicine and pharmacogenomics for Parkinson’s disease . Mov. Disord.32 , 1139 – 1146 ( 2017 ).
- Hill-Burns EM , DebeliusJW , WissemannWTet al. Parkinson’s disease and Parkinson’s disease medications have distinct signatures of the gut microbiome . Mov. Disord.32 , 739 – 749 ( 2017 ).
- Bu LL , YangK , XiongWXet al. Toward precision medicine in Parkinson’s disease . Ann. Transl. Med.4 ( 2 ), 26 ( 2016 ).
- von Coelln R , ShulmanLM . Clinical subtypes and genetic heterogeneity: of lumping and splitting in Parkinson’s disease . Curr. Opin. Neurol.29 , 727 – 734 ( 2016 ).